Neuropathix, Inc. Overview
Pro stress-test →Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics. The company has discovered, developed, and patented a global intellectual property estate, led by its lead clinical target, KLS-13019, as novel therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants.
Strategic Profile
Pro stress-test →The Company's family of patented monotherapeutic molecules focuses on treating oxidative stress-related diseases, chronic pain management, and neurodegenerative disorders. Kannalife's research has been backed by a total of $3.3 million in grant funding from the National Institutes of Health (NIH) under the NIH HEAL Initiative and focused on the treatment of chemotherapy induced peripheral neuropathy (CIPN). The Neuropathix leadership team has more than 40 years of business, marketing and drug development experience with Fortune 500, Pharma and leading Biotechnology firms.
Competitive Landscape
Pro stress-test →Possible competitors to Neuropathix may include Gilgamesh Pharmaceuticals, Alto Neuroscience, and 4E Therapeutics. These early-stage biotech firms compete in pain management, neuroinflammation, and neurodegenerative drug development. Neuropathix's differentiation is claimed through its proprietary KLS-13019 platform with enhanced potency and bioavailability over existing molecules.
Industry Context
Neuropathix, Inc. operates in Neuroprotective therapeutics.
Key facts
Founded: 2010 · Headquarters: Doylestown, Pennsylvania, United States · Employees: 2-10